# Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)

> **NCT03998254** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6000 (estimated)

## Conditions studied

- Papillomavirus Infections

## Interventions

- **DRUG:** V503
- **DRUG:** Gardasil

## Key facts

- **NCT ID:** NCT03998254
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-26
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2022-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03998254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03998254, "Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03998254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*